Migdał, A., et al. (2021) Children with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Treated with Pulmonary Vasodilators—The Pediatric Cardiologist Point of View. Children, 8, Article 326.
https://doi.org/10.3390/children8050326

has been cited by the following article:

• TITLE: Bosentan Is Associated with a Reduction in Right Ventricular Systolic Pressure N-Terminal Pro-Hormone B-Type Natriuretic Peptide Levels in Young Patients with Pulmonary Hypertension

  AUTHORS: Lily M. Landry, Andrew C. Burks, Onyekachukwu Osakwe, Jarrod D. Knudson, Christopher L. Jenks

  KEYWORDS: Pulmonary Arterial Hypertension, Bronchopulmonary Dysplasia, Endothelial Receptor Antagonist, Congenital Heart Disease

  JOURNAL NAME: Open Journal of Pediatrics, Vol.13 No.1, January 9, 2023

  ABSTRACT: Pulmonary hypertension is a rare and potentially fatal disease in children if left untreated. Emerging therapies, including Bosentan, a dual endothelin receptor antagonist, have shown significant benefits in the adult pulmonary hypertension population; however, few studies have assessed the efficacy and safety of endothelin receptor antagonists in infants and young children. Our study was a single-center retrospective analysis of patients less than two years of age with a confirmed diagnosis of pulmonary hypertension and initiated on Bosentan therapy between 2017 and 2020. Twelve cases met eligibility criteria. Demographic data, laboratory data, echocardiographic, and cardiac catheterization data were analyzed. With treatment, there was a statistically significant decrease in mean right ventricular systolic pressure estimated by the tricuspid regurgitation jet (79 ± 23 mmHg reduced to 52 ± 25 mmHg; p